Navigation Links
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
Date:11/5/2007

SAN MARINO, Calif., Nov. 5 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials in the United States for pancreatic cancer, breast cancer and all types of sarcoma in the summer of 2007.

*(LOGO: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

Based on the exceptional safety profile of Rexin-G in the first 18 patients who participated in these U.S.-based clinical trials, and the profound demonstration of single agent efficacy in metastatic osteosarcoma, the FDA approved a Phase II Registration Protocol using intravenous Rexin-G for recurrent or metastatic osteosarcoma that is refractory to known therapies. The study will recruit 20-30 patients in 12-18 months. Children who are at least 10 years of age or older are eligible to participate in the study. The adaptive trial design of this advanced Phase II registration protocol incorporates (i) a dosing schedule based on the patient's estimated tumor burden and not on standard dosing per kilogram body weight or body surface area, and (2) a tumor response evaluation process that is unique to the manner in which osteosarcoma responds favorably to therapy, i.e., with necrosis and increasing calcification in metastatic tumors and decreased glucose utilization using PET-CT imaging studies.

Rexin-G is a tumor-targeted gene medicine that seeks out and destroys both primary tumor and metastatic cancers that have spread throughout the body. Delivered by simple intravenous infusion, Rexin-G has demonstrated unprecedented single-agent efficacy against a broad spectrum of solid tumors where chemotherapy, radiotherapy a
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer and ... cast the,presentation by Harvey Kamil, President and Chief Financial ... in New York on Wednesday,September 17, 2008., The ... NBTY,s web site, (http://www.nbty.com ) on Wednesday, September 17, ...
... Calif., Sept. 11 Abaxis, Inc.,(Nasdaq: ABAX ), ... today that Clint Severson, CEO and,President, will present at ... 17, 2008 at 8:00 a.m. EDT, at the Omni ... Abaxis develops, manufactures and markets portable blood analysis,systems ...
... Kurian, MD, and her colleagues at the Stanford University ... identify women who might have dangerous genetic mutations that ... well for white women. But they seemed to be ... repeatedly surprised when Asian women who the models predicted ...
... Wolters Kluwer Health, a,division of Wolters Kluwer, ... for students, professionals, and institutions in medicine,nursing, ... announced,today the appointment of Scott Lubeck Vice ... Lubeck comes to Wolters Kluwer Health ...
... Sept. 11 Vasculitis,Foundation (VF), the leading organization ... all types of vasculitis, is taking,its advocacy and ... of its,first-ever webinar, Monday, September 22, 12:30 - ... easily accessible information about,vasculitis to the medical community ...
... newly-developed technology at the Delft University of Technology in the ... be a thing of the past. This is the message ... Institute Delft (RID) in an article in university journal ... hospitals are facing a shortage of radio isotopes which means ...
Cached Medicine News:Health News:NBTY to Web Cast Presentation at CL King Best Ideas Conference 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 2Health News:Risk of breast cancer mutations underestimated for Asian women, Stanford study shows 3Health News:Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit 2Health News:Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease 2Health News:Delft University of Technology patent for manufacturing radio isotopes 2
(Date:10/20/2014)... N.Y. , Oct. 20, 2014 Pharmaceutic ... outsourcing facility in Albany, NY ... trials. The company meets and/or exceeds the FDA standards ... and 21 CFR Part 211. The ... the highest levels of quality assurance and quality control. ...
(Date:10/20/2014)... -- Norgine B.V. today announced that the ... preparation, NER1006, presented at the 79 th Annual ... Philadelphia, PA , has met its ... endpoint of cleansing success. The study demonstrated high quality ... in screening colonoscopy patients. [1] (Logo: ...
(Date:10/19/2014)... , October 20, 2014 Shire plc (LSE: ... , Interim Chief Financial Officer (CFO), has notified the Board of ... to pursue a new career opportunity as CFO of Severn Trent ... and the company will commence a search for a new CFO ... "James has helped build and lead a high-quality finance team ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Dec. 22, 2010 SCOLR Pharma, Inc., a Delaware corporation ... it notified the NYSE Amex Exchange (the "Exchange") of its ... Exchange Commission (the "Commission") to effect the voluntary withdrawal of ... to file the Form 25 with the Commission on or ...
... WPI ) today announced the U.S. Food and ... – the first and only low dose oral contraceptive to ... chewable form, with four 75 mg ferrous fumarate (iron) placebo ... proven effective in lowering the risk of pregnancy. ...
Cached Medicine Technology:SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 2SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 3SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange 4Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: